Glenmark Pharmaceuticals Inc., USA (Glenmark), a research-led, global pharmaceutical company, announces the launch of vancomycin hydrochloride for injection USP, 750 mg/vial, 1.25 g/vial and 1.5 ...

1Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is only approved for the indication(s) listed in Glenmark's approved label.

while the 2.5 mg vial will be priced at Rs 3,500, the 5 mg vial will be priced at Rs 4,375. “This India-specific pricing reflects Lilly’s commitment to expanding access to innovative treatment ...

This has come amid rising cases of obesity and diabetes in the country. A 5 mg vial of the once-weekly drug has been priced at Rs 4,375, while a 2.5 mg vial will cost Rs 3,500. Mounjaro ...

1 Glenmark's Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is only approved for the indication(s) listed in Glenmark's approved label. 2 Market includes brand and all ...

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- ...

Eli Lilly launches 7.5 mg and 10 mg Zepbound vials for $499, also reducing prices for 2.5 mg and 5 mg vials. Self-pay patients can access Zepbound vials through LillyDirect, bypassing third-party ...

announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program. 1 Lilly also reduced the price of the 2.5 mg ...

Durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and ... The list price is £592 for a 120‑mg vial and £2,466 for a 500‑mg vial (excluding VAT; BNF online accessed October 2024). The ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...

in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease ...

have received FDA approval for their drug Niktimvo in 9 mg and 22 mg vial sizes. Niktimvo was approved in August 2024 for the treatment of chronic graft-versus-host disease after failure of at ...